Property and casualty insurers, as well as life insurers, are expected to benefit from Donald Trump's presidential election ...

Evercore ISI analyst Liisa Bayko upgraded Editas Medicine (EDIT) to Outperform from In Line with a price target of $7, up from $3. Editas has ...

The president and CEO of Evercore Wealth Management and Evercore Trust explains how he built a business to serve the complex ...

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), ...

In anticipation of Federal Reserve Chair Jerome Powell’s speech at the Jackson Hole Economic Symposium, Evercore ISI analysts have indicated that Powell will outline a flexible approach to rate cuts.

Proxies for former President Donald Trump's trade policies — specifically bitcoin and the Chinese yuan — can help gauge what market participants are making of the election results, Julian Emanuel, ...

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

Overall, the bull market “looks to remain intact,” Evercore’s team emphasizes. However, it adds that the S&P 500 index has the potential for a post-election “meltup” to 6,500 or experience a sell-off.

Evercore ISI Recognized as the #1 Firm in U.S. Equity Research for the Third Consecutive Year ...

Aidan Hall; Analyst; Keefe, Bruyette, & Woods, Inc. Good morning and welcome to the Evercore third-quarter 2024 earnings conference call. (Operator Instructions) I will now turn the call over to ...

Evercore ISI analyst Kirk Materne highlighted multiple positives in Microsoft's report, including 16% constant-currency revenue growth for Microsoft 365 Commercial and increasing contributions from ...

NEW YORK, October 29, 2024--(BUSINESS WIRE)--Evercore ISI was ranked No. 1 among all firms for top-ranked analysts on a weighted basis in Extel’s (previously Institutional Investor) All-America ...